D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the year ending December 31, 2023. For the year ending December 31, 2023, the company expects net sales of JPY 400 million, operating loss of JPY 1,400 million and loss attributable to owners of parent of JPY 1,390 million or JPY 44.60 per share.